Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3710]

Josep Tabernero to head ESMO

Josep Tabernero to head ESMO

Genome-wide risk associations for mucinous ovarian carcinoma

Genome-wide risk associations for mucinous ovarian carcinoma

Mouse models of human colorectal cancer generated through chemokine targeting

Mouse models of human colorectal cancer generated through chemokine targeting

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Stabilised mutant p53 is an important determinant of tumour survival and a valid drug target

Stabilised mutant p53 is an important determinant of tumour survival and a valid drug target

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Scientists discover new molecules that kill cancer cells and protect healthy cells

Scientists discover new molecules that kill cancer cells and protect healthy cells

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

More from ecancer